...
首页> 外文期刊>American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons >Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols.
【24h】

Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols.

机译:HLA和ABO抗体屏障的肾移植:将配对捐赠与脱敏方案相结合。

获取原文
获取原文并翻译 | 示例
           

摘要

The field of desensitization and incompatible transplantation has made great gains over the past decade. There are now several options and effective therapies for many patients who face antibody barriers. Kidney paired donation (KPD) and desensitization have traditionally been considered competing strategies and patients have been offered one or the other without regard for the probability of a successful outcome. It is now possible to predict which donor/recipient phenotypes will benefit from each of these modalities. KPD should be favored among patients with immunologic phenotypes that are likely to match without prolonged waiting times. However, as many as 50% of patients with incompatible donors will fail to find a match in a KPD pool and many of these patients could be desensitized to their donor. Positive crossmatch and ABO incompatible transplantation has been accomplished in selective cases without the need for heavy immunosuppression or B-cell ablative therapy. Patients who are both difficult-to-match due to broad sensitization and hard-to-desensitize because of strong donor reactivity can often be successfully transplanted through a combination of desensitization and KPD. Using these various modalities it is estimated that most patients with incompatible live donors can undergo successful renal transplantation.
机译:在过去十年中,脱敏和移植不相容的领域已经取得了巨大的收益。现在有几个面部抗体障碍的患者有几种选择和有效的疗法。肾脏成对捐赠(KPD)和脱敏传统上被认为是竞争策略,并且患者已经提供了一个或另一个,而不考虑成功结果的可能性。现在可以预测哪些捐赠者/受体表型将受益于这些方式中的每一个。 KPD应该受到免疫表型患者的青睐,这些患者可能会匹配而没有长时间的等待时间。然而,多达50%的捐赠者的患者将无法在KPD游泳池中找到匹配,并且许多患者可以脱铜给他们的供体。在无需沉重免疫抑制或B细胞烧蚀疗法的选择性情况下已经完成了阳性交叉型和ABO不相容的移植。由于具有强大的供体反应性而难以致敏并且难以脱敏而难以匹配的患者通常可以通过脱敏和KPD的组合成功地移植。使用这些各种方式估计大多数现场捐赠者的患者可以接受成功的肾移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号